Response to Response

Response to Response The response by Fred Gould and Jennifer Kuzma1 to my description of the fundamental flaws in two reports from the National Academy of Science/National Research Council2 is reminiscent of the story about the drunk searching for his lost keys under the streetlight. A friend who happens upon the fellow asks if he's sure that he lost them there. The drunk answers, "No, I'm sure they're not here, but the light is better." Gould and Kuzma concede the consensus that the risk-r

Written byHenry Miller
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The response by Fred Gould and Jennifer Kuzma1 to my description of the fundamental flaws in two reports from the National Academy of Science/National Research Council2 is reminiscent of the story about the drunk searching for his lost keys under the streetlight. A friend who happens upon the fellow asks if he's sure that he lost them there. The drunk answers, "No, I'm sure they're not here, but the light is better."

Gould and Kuzma concede the consensus that the risk-related characteristics of a product, rather than the techniques used to make it, should determine the need for and extent of regulation. But they make an insupportable leap of logic by asserting that if "this principle is taken to its simplest logical conclusion, there are two options: regulate all plant varieties or regulate none," and that because both are unacceptable, a tiered approach applicable only to recombinant DNA-modified plants is ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies